944.8000 18.55 (2.00%)
NSE Jun 13, 2025 15:31 PM
Volume: 53,126
 

944.80
2.00%
ICICI Securities Limited
In FY23, Tatva Chintan (TATVA) earnings were hurt from a downcycle in its SDA business, which should resume growing FY24 onwards. The addition of a significant new customer to its SDA has the potential to propel growth in the near future. PASC segment will likely reap the benefit of products under qualification and long-term growth on the back of a robust pipeline and cleaner chemistry positioning.
Tatva Chintan Pharma Chem Ltd. is trading above all available SMAs
More from Tatva Chintan Pharma Chem Ltd.
Recommended